$Longeveron (LGVN.US)$
longeveron.com/...
why can't break thru $3?
Alzheimer's Disease and HLHS
Alzheimer's disease therapeutics market is expected to reach USD 6.3 billion by 2034, growing at a CAGR of 6.8% during the same period.

$Longeveron (LGVN.US)$
Longeveron Reports Positive FDA Type C Meeting on BLA Pathway for Lomecel-B in HLHS
The Phase 2B trial for the CLEAR MIND study, which evaluates Lomecel-B for mild Alzheimer's disease, is anticipated to start following a meeting with the FDA before the end of 2024. This meeting aims to outline the future clinical and regulatory strategy for Lomecel-B, based on the positive results from the Phase 2A trial. Specific timelines for initiating the Phase 2B trial will depend on t...

$Longeveron (LGVN.US)$
How might Lomecel-B's approval influence other Alzheimer's treatments
If Lomecel-B receives FDA approval, it could significantly influence other Alzheimer's treatments in several ways:
1. **Market Dynamics**: Approval may shift market focus towards regenerative therapies, encouraging more investment and research in stem cell and regenerative medicine approaches for Alzheimer's, potentially leading to a broader range of treatment options.
2. **Competitive Pressure**: Esta...

$Longeveron (LGVN.US)$
if Fda approved what will happen
If the FDA approves Lomecel-B for Alzheimer's disease, several significant outcomes can be expected:
1. **Market Launch**: Lomecel-B would become available for prescription, providing a new treatment option for patients with mild Alzheimer's disease, potentially impacting the estimated $15.9 billion Alzheimer's treatment market by 2030[1].
2. **Increased Stock Value**: Approval could lead to a substantial increase in Longeveron's stock pr...

$Longeveron (LGVN.US)$ someone is manipulative on the price

$Longeveron (LGVN.US)$
fast track means in a couple of months if they passed the phase 3 trial in terms of efficacy and safety they could be granted approval..
CEO/CSO has been buying up shares since April 2024 in a sizable amount.
U.S. FDA granted Lomecel-B™ both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s disease
Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS ha...

$Longeveron (LGVN.US)$
biggest player in the segment and it's value

$Longeveron (LGVN.US)$
Alzheimer’s Disease Therapeutics Market Value to Reach USD 30.8 Billion by 2033 | Driven by the Advancements in Neurological Research
with such market size and effective treatment yet to establish. this really is promising with US holding to 42.5% of the market size.

$Longeveron (LGVN.US)$
The Alzheimer's disease market is expected to grow in the coming years due to a number of factors, including increased awareness, advancements in drug development, and rising prevalence of the disease:
Market size
The global Alzheimer's therapeutics market was valued at $4.82 billion in 2023 and is expected to reach $8.18 billion by 2032. The global Alzheimer's drugs market was valued at $7.7 billion in 2023 and is expected to reach $12.4 billion by 2032.
Market drivers...